Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients

Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients

Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to evaluate its ready-to-use, room temperature-stable glucagon in patients with Type 1 diabetes who suffer from exercise-induced hypoglycemia (EIH). This is a critical step for the company as it looks to […]

TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for the treatment of inherited Epidermolysis Bullosa (EB). This trial marks a significant advancement in the quest for effective therapies for this challenging condition. The Phase 2 trial of AC-203 is […]